IP Library Granted Patent US 12,678,473
Granted Patent B2
US 12,678,473 · App. 17/726,731 · Granted Jul 14, 2026

Muscle quality improvement agent

Inventors: Kyoko Miura (Kawasaki, JP); Yoshiro Kitahara (Kawasaki, JP); Haruka Ohashi (Kawasaki, JP)
Assignee: AJINOMOTO CO., INC.
A61K38/05A23L33/18A23L33/40A61K9/0056A61K38/06A61P21/00A61P21/06C07K5/0215A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,678,473
App. No.
17/726,731
Filed
Apr 22, 2022
Granted
Jul 14, 2026
Kind
B2
Art Unit
1654
USPC
514/5.5
Abstract

Agents containing γ-glutamyl peptide can prevent a decline in muscle quality and improve muscle quality even when exercise is limited, and further, can effectively enhance the effect of exercise even when the exercise is of a level free of undue efforts.

Claims (10)

1 . A method for improving muscle quality, comprising administering to a subject in need thereof an effective amount of a γ-glutamyl peptide,

wherein said γ-glutamyl peptide is γ-glutamyl valine.

2 . The method according to claim 1 , wherein said γ-glutamyl peptide is administered in an amount of 0.01 mg/kg body weight to 10 g/kg body weight per day.

3 . The method according to claim 1 , wherein said γ-glutamyl peptide is administered in an amount of 0.05 mg/kg body weight to 5 g/kg body weight per day.

4 . The method according to claim 1 , wherein said γ-glutamyl peptide is administered in an amount of 0.1 mg/kg body weight to 1 g/kg body weight per day.

5 . The method according to claim 1 , wherein said subject is human.

6 . The method according to claim 1 , wherein said subject is an elderly person in need of nursing care.

7 . The method according to claim 1 , wherein said subject is experiencing a decline in physical function.

8 . The method according to claim 1 , wherein said subject is under restriction of exercise due to illness or injury.

9 . The method according to claim 1 , wherein the γ-glutamyl peptide is administered in the form of a composition which comprises said γ-glutamyl peptide in a concentration of 0.001 mM to 100 mM.